PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Extended DAPT Cuts Ischemic Events in Multivessel CAD

DAPT-MVD demonstrates that 12 additional months of clopidogrel plus aspirin reduces ischemic events without excess bleeding in stable, event-free multivessel disease patients, a distinctly favorable risk-benefit profile relative to prior extension trials.
clopidogrelaspirindual antiplatelet therapyDAPTP2Y12 inhibitormultivessel coronary artery diseasedrug-eluting stentsecondary preventionmyocardial infarctionACSrandomized controlled trialDAPT-MVD Cardiology / Anticoagulation

Background Information

Extended DAPT reduces ischemic events post-stent in multivessel CAD.

Extended dual antiplatelet therapy (DAPT) may improve outcomes for patients with multivessel coronary artery disease (CAD) post-stent implantation. Extended DAPT reduced ischemic events compared to aspirin alone without significantly increasing major bleeding in multivessel CAD patients. Provides evidence for prolonging DAPT in multivessel CAD post-stent. Limitation: specific to those who tolerated 12 months of initial therapy. Extended DAPT reduces ischemic events without increasing major bleeding after stent implantation in multivessel CAD.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Tian J, Wang Z, Wang Y, Wang F, Peng X, Xiao J, Li C, Hou X, Tong Q, Yu X, Gao G, Zhao P, Zhao J, Liu Y, Qin Z, Lu H, Zhang S, Li S, Weng Z, Tang H, He Y, Zhang C, Liu Y, Jiang J, Zhang J, Cai L, Xiu L, Mintz GS, Wang D, Stone GW, Yu B, DAPT-MVD Trial Investigators

Citation: Tian J, Wang Z, Wang Y, et al. Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease. The New England journal of medicine. 2026;395(3):233-242. doi:10.1056/NEJMoa2517588

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →